Literature DB >> 29739716

The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.

Heeji Lim1, Hyun Ju In1, Jung-Ah Lee2, Jung Sik Yoo3, Sang-Won Lee4, Gyung Tae Chung3, Young Ki Choi5, Jae Keun Chung6, Sun Ju Cho6, June-Woo Lee7.   

Abstract

Coxsackievirus belongs to the Enterovirus genus of the Picornaviridae family and is one of the major pathogens associated with human hand, foot, and mouth disease (HFMD). Historically, outbreaks of HFMD have mainly been caused by enterovirus 71 and coxsackievirus A16. Recently, coxsackieviruses A6 and A10 have been associated with increased occurrences of sporadic HFMD cases and outbreak events globally. In this study, the immunogenicity of coxsackieviruses A6, A10, and A16 (CA6, CA10, and CA16), which were inactivated by formalin or β-propiolactone (BPL) under different conditions, was evaluated as multivalent vaccine candidates. CA6 induced similar immune responses with both inactivation methods, and the immune efficacy of CA10 and CA16 was better following inactivation with BPL than with formalin. There was no sufficient cross-reactivity or cross-protectivity against heterologous strains in groups vaccinated with the BPL-inactivated (BI) monovalent vaccine. Sufficient neutralizing antibody and cell-mediated immune responses were induced in the BI-trivalent vaccinated group. These findings suggest that BI-CA6, CA10, and CA16 are potential multivalent vaccine candidates and that a multivalent vaccine is needed to control HFMD. The coxsackievirus multivalent vaccine could be useful for the development of effective HFMD vaccines.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coxsackievirus; Inactivated vaccine; Multivalent

Mesh:

Substances:

Year:  2018        PMID: 29739716     DOI: 10.1016/j.vaccine.2018.05.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge.

Authors:  Ruixiao Du; Qunying Mao; Yalin Hu; Shuhui Lang; Shiyang Sun; Kelei Li; Fan Gao; Lianlian Bian; Ce Yang; Bopei Cui; Longfa Xu; Tong Cheng; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

2.  A uniform quantitative enzyme-linked immunosorbent assay for Coxsackievirus A16 antigen in vaccine.

Authors:  Bopei Cui; Fang Cai; Fan Gao; Lianlian Bian; Ruixia Wu; Ruixiao Du; Xing Wu; Pei Liu; Lifang Song; Lisha Cui; Yadi Yuan; Siyuan Liu; Xiangzhong Ye; Tong Cheng; Qunying Mao; Qiang Gao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2020-08-04       Impact factor: 3.452

3.  Incidence of Infection of Enterovirus 71 and Coxsackieviruses A6 and A16 among Household Contacts of Index Cases in Dong Thap Province, Southern Vietnam.

Authors:  C Q Hoang; H D Nguyen; N X Ho; T H T Vu; T T M Pham; K T Nguyen; H T Nguyen; L T Hoang; H Clapham; T T T Nguyen; L T Phan
Journal:  Biomed Res Int       Date:  2020-11-19       Impact factor: 3.411

Review 4.  Advances in the design and development of SARS-CoV-2 vaccines.

Authors:  Xue-Liang Peng; Ji-Si-Yu Cheng; Hai-Lun Gong; Meng-Di Yuan; Xiao-Hong Zhao; Zibiao Li; Dai-Xu Wei
Journal:  Mil Med Res       Date:  2021-12-16

5.  Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains.

Authors:  Yaqian Huo; Jinghuan Yang; Pei Liu; Bopei Cui; Chenfei Wang; Siyuan Liu; Fangyu Dong; Xujia Yan; Lianlian Bian; Fan Gao; Xing Wu; Jiuyue Zhou; Tong Cheng; Xiuling Li; Qunying Mao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2021-11-10       Impact factor: 3.452

Review 6.  Viruses as tools in gene therapy, vaccine development, and cancer treatment.

Authors:  Musab Bin Umair; Fujimura Nao Akusa; Hadia Kashif; Fatima Butt; Marium Azhar; Iqra Munir; Muhammad Ahmed; Wajeeha Khalil; Hafiz Sharyar; Shazia Rafique; Muhammad Shahid; Samia Afzal
Journal:  Arch Virol       Date:  2022-04-24       Impact factor: 2.685

7.  Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China.

Authors:  Jia Xie; Xiao-Han Yang; Si-Qi Hu; Wen-Li Zhan; Chang-Bin Zhang; Hong Liu; Hong-Yu Zhao; Hui-Ying Chai; Ke-Yi Chen; Qian-Yi Du; Pan Liu; Ai-Hua Yin; Ming-Yong Luo
Journal:  BMC Infect Dis       Date:  2020-04-07       Impact factor: 3.090

8.  Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease.

Authors:  Lam Anh Nguyet; Tran Tan Thanh; Le Nguyen Thanh Nhan; Nguyen Thi Thu Hong; Le Nguyen Truc Nhu; Hoang Minh Tu Van; Nguyen Thi Han Ny; Nguyen To Anh; Do Duong Kim Han; Ha Manh Tuan; Vu Quang Huy; Ho Lu Viet; Hoang Quoc Cuong; Nguyen Thi Thanh Thao; Do Chau Viet; Truong Huu Khanh; Louise Thwaites; Hannah Clapham; Nguyen Thanh Hung; Nguyen Van Vinh Chau; Guy Thwaites; Do Quang Ha; H Rogier van Doorn; Le Van Tan
Journal:  Emerg Infect Dis       Date:  2020-02       Impact factor: 6.883

Review 9.  From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD).

Authors:  Xiangchuan He; Miaomiao Zhang; Chen Zhao; Peiyong Zheng; Xiaoyan Zhang; Jianqing Xu
Journal:  Virol Sin       Date:  2020-09-30       Impact factor: 4.327

10.  Immune responses of a CV-A16 live attenuated candidate strain and its protective effects in rhesus monkeys.

Authors:  Ting Yang; Tianhong Xie; Hua Li; Xia Song; Lei Yue; Xi Wang; Dong Shen; Kaili Ma; Qinfang Jiang; Runxiang Long; Rong Yang; Xin He; Ye Zhang; Zhongping Xie; Qihan Li
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.